Generics in Singapore industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Singapore
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Singapore
Leading company profiles reveal details of key generics market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the Singapore generics market with five year forecasts by both value and volume
Essential resource for top-line data and analysis covering the Singapore generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Reasons To Buy
What was the size of the Singapore generics market by value in 2016?
What will be the size of the Singapore generics market in 2021?
What factors are affecting the strength of competition in the Singapore generics market?
How has the market performed over the last five years?
How large is Singapore’s generics market in relation to its regional counterparts?
For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
The Singaporean generics market is expected to generate total revenues of $0.3bn in 2016, representing a compound annual growth rate (CAGR) of 8.4% between 2012 and 2016.
Market consumption volume is forecast to decline with a CARC of -0.2% between 2012 and 2016, to reach a total of 87.9% of total pharma volume in 2016.
Singapore has a well-developed pharmaceutical market. The company’s average purchasing power parity (PPP) per capita of GDP was over $61,000 in 2013, $10,000 more than in the US. The country has also been ranked number six healthcare system worldwide by the World Health Organization.